TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04104932

Intervention type: PROCEDURE
Intervention: Open reduction and internal fixation
Description: Open reduction and internal fixation
Study: NCT00792506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
Study: NCT03760328

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Upper Airway Stimulation
Description: hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Airway Stimulation
Description: hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
Study: NCT01712308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT01323816

Intervention type: OTHER
Intervention: Medically directed care
Description: There is no research directed care. Patients are treated as medically indicated.

Intervention type: OTHER
Intervention: Medically directed care
Description: There is no research directed care. Patients are treated as medically indicated.
Study: NCT01236950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils mouthrinse
Description: Commercial mouthrinse with manufacturer's use indication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delmopinol mouthrinse
Description: Commercial mouthrinse with manufacturer's use indication
Study: NCT02949908

Intervention type: DRUG
Intervention: Rebif
Description: Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
Study: NCT02732405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK5172 /MK8742
Description: tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
Study: NCT02878421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electronic cigarette + 16mg nicotine & flavor
Description: comparison of different strengths of nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic cigarette + 0mg nicotine & flavor
Description: comparison of different strengths of nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco cigarette
Description: Participant to remain on traditional cigarettes for 28 days
Study: NCT00001941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daclizumab
Study: NCT03148717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Cytotec

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Cytotec

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet similar in shape, odour and consistency to misoprostol tablet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
Study: NCT01185262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomida and Rituximab
Description: Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1.
Study: NCT01100216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: 4 mg for 12 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stonewall Dissolvable Tobacco Pieces
Description: 5.6 mg nicotine pieces for 12 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Camel Snus Frost
Description: pouches, 6.2 mg nicotine, for 12 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skoal Wintergreen
Description: Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
Study: NCT02603926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
Study: NCT02930525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flow nasal cannula
Description: Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard respiratory care
Description: Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
Study: NCT03769597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol Inj 300 MG/ML
Description: After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
Study: NCT04148963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine
Description: Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled placebo, may repeat x 1 or 2 after 2 hours
Study: NCT01366300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine infusion
Description: Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline infusion)
Description: Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol 1% (intravenous infusion)
Description: Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1% (intravenous infusion)
Description: Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of arterial line
Description: An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of arterial line
Description: An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
Study: NCT02149095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon PEG treprostinil
Study: NCT04437472

Intervention type: OTHER
Intervention: CareSignal
Description: The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
Study: NCT04322786

Intervention type: DRUG
Intervention: ACE inhibitor
Description: Any prescription of ACE inhibitor
Study: NCT00850096

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Nasulin
Description: Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasulin
Description: Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
Study: NCT04499105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell + NaCl 0,9% 2ml
Description: Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
Study: NCT01880567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT03938649

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional IMRT
Description: RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT
Description: RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
Study: NCT04337060

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Single-injection ultrasound-guided bilateral erector spinae plane (ESP) block-Sham
Description: With the patient in the sitting position, 20 ml normal saline will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: after anesthesia induction, paracetamol 1 gr intravenous (IV)+ tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV morphine patient-controlled analgesia (PCA) of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit).
Study: NCT04668170

Intervention type: BIOLOGICAL
Intervention: Blood collection on admission and longitudinally
Description: Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)

Intervention type: BIOLOGICAL
Intervention: Blood collection on their first consultation and 10 to 14 days later
Description: Samples already collected on consultation (D0) and 14 days later
Study: NCT02844907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemic Clamp
Description: A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
Study: NCT00044707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide acetate
Description: Clear, colorless, sterile solution for SC injection.
Study: NCT01075906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine sprinkle capsules
Description: 0.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine sprinkle capsules
Description: 0.3 mg
Study: NCT03325894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465
Description: SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
Study: NCT01823172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Methylene blue dye injection of sentinel lymph node
Description: Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
Study: NCT03398863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cleaning of uterine cavity
Description: Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
Study: NCT03244618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSSP Toothpaste
Description: Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Toothpaste
Description: Toothpaste containing sodium monofluorphosphate
Study: NCT05155722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1308
Description: A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
Study: NCT03950141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and S-1
Description: Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
Study: NCT00757029

Intervention type: GENETIC
Group type: OTHER
Intervention: norepinephrine transporter polymorphism,
Description: OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
Study: NCT02574702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application of a contralateral drainage (Penrose ® device)
Description: application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
Study: NCT02613715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackberry juice with 12% ethanol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackberry juice
Study: NCT05260775

Intervention type: OTHER
Intervention: Evaluation test: cataract surgery steps
Description: The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters

Intervention type: OTHER
Intervention: Evaluation test: cataract surgery steps
Description: The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters

Intervention type: OTHER
Intervention: Evaluation test: cataract surgery steps
Description: The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
Study: NCT02727426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Salt (LS) diet
Description: Intake of less than 2.3 g of salt per day for 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Salt (HS) diet
Description: Intake of 11.2 g of salt per day for 7 days.
Study: NCT03715231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIDEK Gonioscope GS-1
Description: To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Digital Gonioscopic Images
Description: To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
Study: NCT02933905

Intervention type: DRUG
Intervention: Intravitreal Ranibizumab injection

Intervention type: DRUG
Intervention: Intravitreal Ranibizumab injection
Study: NCT00555126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forced Air Warming
Description: Warming after Randomization
Study: NCT04337060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection ultrasound-guided bilateral erector spinae plane block-Lidocaine/Bupivacaine
Description: With the patient in the sitting position, 10 ml 1% lidocaine + 10 ml 0.5% bupivacaine will be administered between the T11 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane.~Intraoperative analgesia: After anesthesia induction, paracetamol 1 gr IV + tenoxicam 20 mg IV + morphine 0.05 mg/kg IV (max 4 mg).~Postoperative analgesia: IV PCA of 0.5 mg/ml morphine (demand dose 1 mg; lockout interval 8 m; 6 mg/h limit).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain follow-up and monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain follow-up and monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 15th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours with two different conditions which are at rest and while couching.If NRS score becomes ≥4 Dexketoprofen 50 mg will be administered (max 4 times).
Study: NCT01927692

Intervention type: OTHER
Intervention: Skin biopsy
Description: An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.

Intervention type: OTHER
Intervention: Single Fiber Electromyography
Description: An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
Study: NCT04315623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation CRRT
Description: Regional citrate anticoagulation Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-anticoagulation CRRT
Description: Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution.
Study: NCT03119610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
Study: NCT00071240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin (recombinant human growth hormone)
Description: 3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin (recombinant human growth hormone)
Description: 3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
Study: NCT02864043

Intervention type: DEVICE
Group type: OTHER
Intervention: NvisionVLE with Real Time Targeting
Description: Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe

Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagogastroduodenoscopy (EGD)
Description: Standard of care EGD